A test kit for differentiating between porcine senecavirus infection or vaccine immunization
By using the tandem expression of the dominant epitope regions of VP2-VP3-VP1 and 3AB-3C recombinant proteins in ELISA detection, the problem of the inability to distinguish between natural infection and vaccine immunization of porcine Seneca virus in existing technologies has been solved, achieving efficient and accurate detection results.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- YANGZHOU UNIV
- Filing Date
- 2025-04-23
- Publication Date
- 2026-07-10
AI Technical Summary
Existing serological testing methods for porcine Seneca virus (SVA) cannot effectively distinguish between natural infection and vaccine immunization, leading to false negative results and diagnostic difficulties.
Recombinant VP2-VP3-VP1 and 3AB-3C proteins coated with antigens were used to distinguish between porcine Seneca virus infection and vaccine immunization using ELISA. The dominant epitope regions of VP2-VP3-VP1 and 3AB-3C proteins were expressed in tandem, and precise detection was achieved by combining specific dilution ratios with enzyme-labeled secondary antibodies.
It achieves precise differentiation between porcine Seneca virus infection and vaccine immunization, with good specificity, sensitivity, repeatability and reproducibility, and has a wider range of applications, effectively distinguishing between natural infection and vaccine immunization.
Smart Images

Figure CN120369942B_ABST